Drugs / XP-006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07334574 | Jan 2026 → Jan 2028 expected | B-cell non-Hodgkin lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XP-006 | “XP-006 personalized tumor mRNA vaccine” NCT07334574 ↗ |
| Modality | Messenger RNA (mRNA) | “XP-006 mRNA Vaccine” NCT07334574 ↗ |